Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

<b>Background</b>: The RV144 trial in Thailand is the only HIV-1 vaccine efficacy trial to date to demonstrate any efficacy. Genetic signatures suggested that antibodies targeting the variable loop 2 (V2) of the HIV-1 envelope played an important protective role. The ALVAC prime and protein boost fo...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Dieter Mielke, Marina Tuyishime, Natasha S. Kelkar, Yunfei Wang, Robert Parks, Sampa Santra, Wes Rountree, LaTonya D. Williams, Tiffany Peters, Nathan Eisel, Sheetal Sawant, Lu Zhang, Derrick Goodman, Shalini Jha, Adam Zalaquett, Pratamesh Ramasubramanian, Sherry Stanfield-Oakley, Gary Matyas, Zoltan Beck, Mangala Rao, Julie Ake, Thomas N. Denny, David C. Montefiori, Margaret E. Ackerman, Lawrence Corey, Georgia D. Tomaras, Bette T. Korber, Barton F. Haynes, Xiaoying Shen, Guido Ferrari
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2025-02-01
Serie:	Vaccines
Ämnen:	HIV-1 subtype C variable loops 1 and 2 correlate of protection systems serology
Länkar:	https://www.mdpi.com/2076-393X/13/3/231
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!